5 Mid-Stage ALS Drugs to Watch | BioSpace

Brain over neurons_Taylor Tieden

Pictured: Illustration of a brain over a neuron background/Taylor Tieden for BioSpace

After a years-long drought, progress in the amyotrophic lateral sclerosis (ALS) space began to accelerate with the 2022 approval of Amylyx’s Relyvrio and Biogen and Ionis’ Qalsody in 2023. But now, that progress appears to have stalled. Earlier this month, Amylyx announced it would pull Relyvrio from the market after a failed Phase III trial, and closely watched trials from Seelos Therapeutics and Sanofi and Denali Therapeutics recently missed their primary endpoints.

“We went from having lots of trials to all of a sudden, there’s not that many right now, or they’re small or early,” Merit Cudkowicz, chair of the neurology department at Massachusetts General Hospital and a leading ALS researcher, told BioSpace.

Graig Suvannavejh, senior biopharmaceuticals and biotechnology equity research analyst at Mizuho Americas, agreed, saying…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks